Navigation Links
Ban On Trans Fats Comes Into Effect From July 1

Trans fats are chemically modified fats rich in cholesterol and known to cause heart disease. They are widely used as a substitute for saturated fats in bakery products//, fried foods like chips, salad dressings and other foods since long. Food prepared using trans fats is also believed to have a longer shelf life.

In a mighty effort to fight Obesity, the members of the New York City Board of Health, voted yesterday to ban the use of huge amounts of artificial trans fats in restaurants and bakeries.

Experts believe that eliminating trans fats will not change the taste of foods, but chefs and restaurant owners disagree, saying it will be difficult and more expensive to replicate the taste and texture of some menu items without them.

The health department’s restaurant inspectors will be in charge of enforcing both the trans fat and calorie regulations. Violators would have to face fines greater than $200. The Board of Health also demands that restaurants, especially fast food outlets, display the calorific value of each menu item on display boards.

The restaurant industry is highly agitated and accuses the government of interference into free enterprise and civil liberties.

“This is a misguided attempt at social engineering by a group of physicians who don’t understand the restaurant industry,” said Dan Flesher, a representative of National Restaurant Association. He said the association would challenge one or both measures legally.

Mayor Bloomberg said, “ the city is not going to take away anybody’s ability to go out and have the kind of food they want, in the quantities they want.”

“We are just trying to make food safer,” he added.

Restaurants have time until next July 1 to reduce usage of oils and margarine. Admissible fat level is a half-gram of trans fat per serving.

Posting caloric content also takes effect next July 1, this should not be a matter of co ncern for large chains restaurants with highly standardized menus.

Source-Medindi
PRI
'"/>




Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
3. Stem Cell Transplants May Be Effective For MS Patients
4. Transforming stem cells to lung cells
5. Alternative to blood Transfusions
6. Need for Blood Transfusions reduced
7. Drugs Deter Heart Disease for Transplant Patients
8. Better Drug for Heart Transplant
9. Kidney Failure after Non-Kidney Transplants
10. Measles Risk in Transplant Patients
11. West Nile and Blood Transfusions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® ... area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony ... Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ...
(Date:12/4/2016)... Washington DC (PRWEB) , ... December 04, 2016 , ... ... Environmental, one of the most certified and experienced Indoor Air Quality Companies in VA, ... Assessment and Remediation Regulations. , The new mold law in the district ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: